Cargando…
A promising biomarker adaptive Phase 2/3 design – Explained and expanded
This short communication concerns a biomarker adaptive Phase 2/3 design for new oncology drugs with an uncertain biomarker effect. Depending on the outcome of an interim analysis for adaptive decision, a Phase 2 study that starts in a biomarker enriched subpopulation may continue to the end without...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684793/ https://www.ncbi.nlm.nih.gov/pubmed/38034840 http://dx.doi.org/10.1016/j.conctc.2023.101229 |